Cell Biotech Co., Ltd. (KOSDAQ: 049960)

Market Cap	99.24B
Revenue (ttm)	52.60B
Net Income (ttm)	10.97B
Shares Out	6.84M
EPS (ttm)	1,603.39
PE Ratio	9.04
Forward PE	n/a
Dividend	450.00 (3.11%)
Ex-Dividend Date	Dec 27, 2024

Volume	8,937
Average Volume	12,422
Open	14,500
Previous Close	14,500
Day's Range	14,130 - 14,500
52-Week Range	11,170 - 16,950
Beta	0.69
RSI	58.21
Earnings Date	Feb 14, 2025

About Cell Biotech

Cell Biotech Co., Ltd., a biotechnology company, develops lactic acid bacteria products in South Korea and internationally. It engages in the probiotics, microbiome, and anticancer new drug businesses. The company sells its products through partnerships with multinational companies and local retailers under the DUOLAC, DUOLAB, LACTOClear, and LAB2PRO brand names. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 111
• Stock Exchange: KOSDAQ
• Ticker Symbol: 049960

Financial Performance

In 2023, Cell Biotech's revenue was 53.79 billion, an increase of 6.46% compared to the previous year's 50.53 billion. Earnings were 6.30 billion, a decrease of -23.87%.